Characterization of Recombinant Human Lactoferrin Expressed in Komagataella phaffii

Abstract

This work presents a thorough characterization of Helaina recombinant human lactoferrin (rhLF, Effera™) expressed in a yeast system at industrial scale for the first time. Proteomic analysis confirmed that its amino acid sequence is identical to that of native human LF. N-linked glycans were detected at three known glycosylation sites, predominantly oligomannose structures. Helaina rhLF's protein secondary structure was nearly identical to that of human milk lactoferrin (hmLF), and small-angle X-ray scattering and analytical ultracentrifugation confirmed well-folded globular structures in solution closely matching the reported crystalline structure of iron-bound native hmLF. Differential scanning calorimetry revealed two distinct denaturation temperatures consistently mirroring those observed for apo- and holo-hmLF. Overall, Helaina rhLF differed from hmLF only in its N-glycans, while affirming high purity and globular structures closely akin to hmLF.

Full Paper

Category
Published Papers
Journal
Analyst (Royal Society of Chemistry)
Publication date
May 26, 2024
Authors
XL
Xiaoning Lu
Xiaoning Lu
PhD analytical chemist; Head of Analytics and Testing at Helaina, developing analytical platforms for glycoprotein and food analysis.
CC
Chad Cummings
Chad Cummings
Lead Scientist, Analytics at Helaina, co-author of the 2024 Analyst paper characterizing Helaina's recombinant human lactoferrin (effera); background from Carnegie Mellon.
UO
Udodili A. Osuala
Udodili A. Osuala
Researcher at Helaina Inc., co-author of the 2024 Analyst paper characterizing recombinant human lactoferrin (effera) expressed in Komagataella phaffii.
NY
Neela H. Yennawar
Neela H. Yennawar
Research Professor; Director, Biomolecular Interactions Core Facility, and Co-Director, X-Ray Crystallography and Scattering Core Facility, Penn State University.
KN
Kevin E. W. Namitz
Kevin E. W. Namitz
Structural biologist; postdoctoral researcher in the Showalter Lab, Penn State University (2020-2024), now a Scientist at LOTTE Biologics.
BH
Brittney Hellner
Brittney Hellner
PhD in chemical engineering (University of Washington, 2019); served as Team Lead, Downstream Engineering at Helaina before moving to Senior Scientist, Biologics Process R&D at Merck.
PB
Pamela B. Besada-Lombana
Pamela B. Besada-Lombana
VP, R&D at Helaina Inc.; PhD in Chemical and Biochemical Engineering, expert in microbial/cell engineering for precision fermentation.
RP
Ross D. Peterson
Ross D. Peterson
PhD; VP of Scientific and Regulatory Affairs at Helaina, leading regulatory strategy and safety/efficacy science for effera lactoferrin.
AC
Anthony J. Clark
Anthony J. Clark
Chief Technology Officer at Helaina, leading precision fermentation and strain development for effera human lactoferrin.

Ready to build the future?

effera® is more than an ingredient; it's a platform for innovation.
If you're ready to move beyond legacy ingredients and create a product that's truly aligned with human biology, we're ready to talk.